Given the similar Zn-based active site of ACER3 and the canonical catalytic mechanism we propose, it is likely that hydroxamates, which display strong binding to Zn centers, may be developed as inhibitors of the ACERs for cancer therapy. The gene discussed is ACER3; the disease is cancer.